DanCann Pharma A/S: The subscription period in DanCann Pharma’s Rights Issue begins today
COPENHAGEN, Denmark, October 31, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the subscription period in DanCann Pharma’s Rights Issue of units begins today. The Rights Issue of units consists of shares and warrants of series TO2 and was resolved upon by the Board of Directors on 21 October 2022 (the "Rights Issue"). The public will also be given the opportunity to register an interest in subscribing in the Rights Issue.The prospectus is available on DanCann Pharma’s website www.dancann.com and on